Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Carmine De AngelisXiaoyong FuMaria Letizia CataldoAgostina NardoneResel PereiraJamunarani VeeraraghavanSarmistha NandaLanfang QinVidyalakshmi SethunathNicholas WangSusan G HilsenbeckMatteo BenelliIlenia MigliaccioCristina GuarducciLuca MalorniLacey M LitchfieldJiangang LiuJoshua DonaldsonPier SelenicaDavid N BrownBritta WeigeltJorge S Reis-FilhoBen H ParkSara A HurvitzDennis J SlamonMothaffar F RimawiValerie M JansenRinath M JeselsohnC Kent OsborneRachel SchiffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Aberrant IFN signaling is associated with intrinsic resistance to CDK4/6i. Experimentally, acquired resistance to palbociclib is associated with activation of the IFN pathway, warranting additional studies to clarify its involvement in resistance to CDK4/6i.